title: Effects of nucleus basalis lesions on the muscarinic and nicotinic modulation of [3H]acetylcholine release in the rat cerebral cortex.
abstract: Presynaptic muscarinic and nicotinic receptors in the cerebral cortex reportedly inhibit and increase acetylcholine (ACh) release, respectively. In this study, we investigated whether these receptors reside on cholinergic nerve terminals projecting to the cerebral cortex from the nucleus basalis magnocellularis (nbm). Adult male rats received unilateral infusions of ibotenic acid (5 micrograms/1 microliter) in the nbm. Two weeks later, cerebral cortical cholinergic markers (choline acetyltransferase activity, high-affinity choline uptake, and coupled ACh synthesis) were significantly reduced in synaptosomes prepared from the lesioned hemispheres compared to contralateral controls. The depolarization-induced release of [3H]ACh from these synaptosomes was also reduced in the lesioned hemispheres, reflecting the reduced synthesis of transmitter. However, the nbm lesions had no effect on the inhibition of release induced by 100 microM oxotremorine. Synaptosomal [3H]ACh release was not altered by nicotine or the nicotinic agonists anabaseine and 2-(3-pyridyl)-1,4,5,6-tetrahydropyrimidine. Nicotine (10-100 microM) did increase [3H]ACh release in control and lesioned hemispheres in cortical minces, but to a similar extent. These results suggest that neither muscarinic nor nicotinic receptors modulating ACh release reside on nbm-cholinergic terminals.
authors: Department of Pharmacology and Experimental Therapeutics, University of Florida School of Medicine, J. H. Miller Health Center, Gainesville 32610.
authors: E M
authors: EM
authors: Meyer
authors: G W
authors: GW
authors: Arendash
authors: J H
authors: JH
authors: Judkins
authors: L
authors: L
authors: Ying
authors: C
authors: C
authors: Wade
authors: W R
authors: WR
authors: Kem
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000691:Anabasine / Q000494:pharmacology; D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D007051:Ibotenic Acid / Q000494:pharmacology; D008297:Male; D009538:Nicotine / Q000494:pharmacology; D009847:Olivary Nucleus / Q000187:drug effects / Q000502:physiology*; D010095:Oxotremorine / Q000494:pharmacology; D011188:Potassium / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011976:Receptors, Muscarinic / Q000502:physiology*; D011978:Receptors, Nicotinic / Q000502:physiology*; D013574:Synaptosomes / Q000378:metabolism
chemical_list: D011743:Pyrimidines; D011976:Receptors, Muscarinic; D011978:Receptors, Nicotinic; D007051:Ibotenic Acid; C054149:2-(3-pyridyl)-1,4,5,6-tetrahydropyrimidine; D010095:Oxotremorine; D009538:Nicotine; D002795:Choline O-Acetyltransferase; D000691:Anabasine; D000109:Acetylcholine; D011188:Potassium